Industry Profile

Rare Disease Therapeutics

Target researchers — Molecular geneticists, enzymologists, and translational researchers specializing in enzyme replacement therapy, gene therapy, antisense oligonucleotides, substrate reduction, and natural history characterization of ultra-rare conditions

Rare disease therapeutics address conditions affecting fewer than 200,000 patients using gene therapy, enzyme replacement, and RNA modulation. Orphan drug designation and premium pricing support returns despite small patient pools, making this industry highly motivated to partner with academic researchers who own rare disease cohorts, biobanks, and foundational mechanistic IP.

Key Companies